Parkinson’s disease is commonly described as a disorder of movement. More precisely, it’s a disorder of automatic movement control.
The earliest change is loss of automatic movement. Actions that once required no conscious attention, such as arm swing while walking, handwriting or voice projection, begin to demand effort. Tremor, the most recognisable sign, often appears only after these subtler changes have taken hold.
A growing neurological condition
Parkinson's disease is now regarded as the fastest growing neurological disorder worldwide. More than 8.5 million people globally are estimated to be living with Parkinson’s disease, and prevalence has more than doubled over the past generation. The rise reflects ageing populations, longer survival and improved recognition.
Most diagnoses occur after 60, although younger-onset cases are recognised. Men are affected slightly more often than women. A minority of cases are linked to identifiable genetic mutations. For most individuals, no single cause is found.
The rise in Parkinson’s disease reflects more than demographics. Longer lifespans expose age-related neurodegeneration, while environmental and occupational exposures remain under investigation. Clinicians are encountering the condition with increasing frequency in routine practice.
What changes in the brain
Parkinson’s disease develops when dopamine-producing neurons in the substantia nigra gradually degenerate. Dopamine modulates motor circuits that enable smooth, automatic movement. As dopamine declines, movement becomes slower and less fluid.
Parkinson’s disease can present with subtle non-motor symptoms long before the more recognisable motor features appear. Dr Ahmad, a neurologist, explains that among the lesser-known early signs to be aware of are a reduced sense of smell, persistent constipation, and noticeable changes in sleep patterns.
One particularly important early indicator is REM sleep behaviour disorder (RBD), a condition in which individuals physically act out vivid dreams during sleep. This may precede the development of motor symptoms by several years. Recognising these early changes allows for earlier medical evaluation and more informed monitoring over time.
However, Dr Ahmad emphasises that developing REM sleep behaviour disorder doesn’t necessarily mean a person will go on to develop Parkinson’s disease. Rather, it’s considered a marker of elevated risk, and its presence may prompt clinicians to monitor neurological health more closely over time.
Early changes and diagnostic delay
Parkinson’s disease is identified by evolving patterns rather than isolated symptoms. Slower execution of routine tasks, reduced arm swing on one side, softer speech and progressively smaller handwriting may signal altered motor control. Acting out dreams or diminished smell may accompany these changes.
Because progression is gradual, early features are often attributed to benign variation. Diagnosis may therefore be delayed, particularly in the absence of tremor. Early diagnostic delay does not prevent treatment, but it can postpone rehabilitation planning, structured monitoring and coordinated care that support long-term function. There’s no confirmatory blood test; diagnosis remains clinical, grounded in history and neurological examination.
Parkinson’s disease is primarily a clinical diagnosis, meaning it’s based on medical history and neurological examination rather than a single definitive test. In the earliest stages, however, symptoms can be subtle, variable, or overlap with other conditions, making diagnosis challenging. This is particularly true in younger individuals or in cases with atypical features, where the presentation may not follow the classic pattern.
When diagnostic uncertainty arises, certain investigations can help support the likelihood of Parkinson’s disease by identifying degenerative changes in the nigrostriatal system, the pathway responsible for dopamine production and motor control.
Emerging biomarkers are also being studied for their potential to detect disease earlier and more accurately. These include:
- Alpha-synuclein, a protein that accumulates abnormally in Parkinson’s disease
- Phosphorylated alpha-synuclein, a modified form associated with pathological changes
- DOPA decarboxylase (DDC), an enzyme involved in dopamine synthesis
While these biomarkers may indicate early disease processes and a higher probability of developing Parkinson’s, they’re not yet used as standalone diagnostic tools in routine clinical practice.
Imaging studies can also provide supportive evidence in selected cases. These include:
- MRI brain with a Parkinson’s disease protocol, which may help exclude other causes and detect structural changes
- Dopamine transporter (DAT) scan, which assesses dopamine activity in the brain and can reveal reduced dopaminergic function consistent with Parkinson’s disease
Together, these tools are improving the ability to detect Parkinson’s earlier, particularly in complex or unclear cases, although clinical evaluation remains the cornerstone of diagnosis.
Who is at higher risk?
Risk increases with age. Most diagnoses occur after 60, though younger-onset Parkinson’s disease is recognised. Men are slightly more commonly affected. Genetic mutations account for a minority of cases. Environmental contributors, including pesticide exposure and head trauma, are under study, but for most individuals no precipitating factor is identified.
Persistent, progressive asymmetrical change carries greater clinical significance than isolated or transient symptoms.
When to seek assessment
Symptoms that persist for weeks to months and gradually worsen warrant medical review, particularly when one side of the body is affected more than the other.
Evaluation typically begins with a General Practitioner. If Parkinson’s disease is suspected, referral is made to a neurologist trained in movement disorders. Neurology specialists differentiate Parkinson’s disease from essential tremor and related syndromes through structured assessment.
Emerging research has led to the hypothesis that, in some individuals, Parkinson’s disease may originate in the gut rather than the brain. One proposed mechanism suggests that misfolding of the protein alpha-synuclein may begin in the gastrointestinal tract. These abnormal protein changes may then spread to the brain via the vagus nerve, contributing to inflammation and progressive neurodegeneration.
Alterations in the gut microbiome, known as gut dysbiosis, have also been observed in people with Parkinson’s disease. Dysbiosis may influence the production of substances such as lipopolysaccharides (LPS) and short-chain fatty acids (SCFAs), which can affect inflammatory pathways and potentially accelerate neuronal damage. While this research is still evolving, it has strengthened interest in the gut–brain axis as a contributing factor in disease development.
Importantly, these findings don’t yet prove that Parkinson’s begins in the gut in all cases, nor do they establish a direct preventive strategy. However, they suggest that maintaining gut health through a balanced diet, regular physical activity and broader healthy lifestyle habits may help support a more stable gut environment and reduce harmful metabolites. Ongoing research continues to explore whether modulating the gut microbiome could play a future role in risk reduction or treatment strategies.
Dr Ahmad notes that if future research were to confirm that the gut is the primary source of the neurodegenerative process leading to Parkinson’s disease, this could open the door to new possibilities for both treatment and prevention. If this mechanism were definitively proven, he says he firmly believes that therapies targeting the gut could one day play a role in both treating and potentially preventing Parkinson’s disease.
How to describe symptoms clearly
Parkinson’s disease is diagnosed through pattern recognition. General statements such as “I feel slower” are less helpful than specific examples.
Before a consultation, consider documenting:
A concise timeline often improves diagnostic precision.
In the early years of Parkinson’s disease, often described as the “honeymoon period”, symptoms typically respond well to relatively low doses of anti-Parkinson’s medications. During this phase, symptom control can be stable and functional independence largely maintained.
As the condition progresses, however, medication requirements usually increase. Over time, fluctuations in response and the emergence of more complex symptoms may require closer adjustment of therapy. In the more advanced stages, management often shifts to a multidisciplinary approach involving neurologists, rehabilitation specialists, physiotherapists, speech therapists and other allied health professionals.
Dr Ahmad explains that quality of life remains the central guiding principle in treatment decisions. In selected patients, surgical interventions such as deep brain stimulation (DBS) may be considered to help manage motor complications and improve daily functioning.
In addition to medication and, where appropriate, surgical intervention, rehabilitation and lifestyle strategies play a critical role throughout the disease course. Regular exercise, weight management, balanced nutrition and adequate sleep are key components in maintaining mobility, stability and overall wellbeing. These measures don’t replace medical treatment, but they can significantly support long-term outcomes and functional independence.
When clinicians refer to quality of life in Parkinson’s disease, Dr Ahmad explains that the definition varies widely between individuals. For some patients, maintaining independence in day-to-day activities may be the main priority. For others, particularly those with demanding professional or public roles, maintaining a higher level of physical and cognitive function may be essential.
These differences often shape treatment decisions, with clinicians adjusting therapy or considering options such as deep brain stimulation when appropriate to help maintain the patient’s quality of life.
Living with Parkinson’s disease
Parkinson’s disease influences more than movement. Changes in facial expression, voice and cognition can affect professional and social interactions. Comprehensive care addresses both motor and non-motor dimensions.
Caregivers often play a central role in recognising progression, supporting medication schedules and encouraging participation in rehabilitation. Because changes may be gradual, family members frequently notice subtle shifts in speech, balance or daily function before they’re clinically apparent. Structured care planning therefore benefits from including caregivers early rather than only after functional decline becomes significant.
Multiple novel treatments for Parkinson’s disease are currently under investigation, although no definitive breakthrough has emerged so far. Gene therapy is one of the most actively studied approaches. Gene therapy aims to silence, replace or correct defective genes involved in disease pathways. Early-phase clinical trials, including Phase I studies, are underway to evaluate safety and feasibility.
One of the motivations behind gene therapy research is the limitation of existing medications, which can be associated with significant side effects over time. Targeted gene-based approaches may, in theory, offer more precise intervention and potentially reduce some treatment-related complications, although this remains under evaluation.
Stem cell therapy is another area of ongoing research. Various sources of stem cells are being explored, including embryonic stem cells, adult-derived or tissue-specific stem cells, umbilical cord stem cells, mesenchymal stem cells, induced pluripotent stem cells and human parthenogenetic stem cells. Several Phase I and Phase II trials are in progress to assess safety, integration and functional benefit.
While these investigational therapies continue to evolve, it’s important to recognise that established treatments already help many patients maintain function and quality of life. These include deep brain stimulation (DBS) and high-intensity focused ultrasound (HIFU), both of which are used in carefully selected individuals to manage motor symptoms when medication alone is insufficient.
Key takeaways
Parkinson’s disease is a disorder of automatic movement control.
Non-motor symptoms may precede motor signs.
More than 8.5 million people worldwide are living with Parkinson’s disease.
Diagnosis remains clinical and pattern-based.
Treatment strategies evolve over time.
Rehabilitation plays a central role in preserving function.
Parkinson’s disease reduces automatic movement. Actions that once unfolded without thought begin to require deliberate control. Recognising that transition early doesn’t alter the chronic course of the condition, but it allows earlier intervention, clearer planning and preservation of functional independence for as long as possible.
Dr Mohammed Tauqeer Ahmad
Neurologist, Medical Director
Neurology International Clinic, Gleneagles Hospital, Singapore
This article was produced by Healthful For You. The views and opinions expressed throughout are those of the authors and do not necessarily reflect those of the Expert Contributor. The Expert Contributor has provided input solely for the EXPERT INSIGHT and TIP segments, based on their professional expertise. These comments are intended to offer general guidance and may not apply to all individuals. Any interpretations or conclusions beyond that section are those of Healthful For You. This article is not a substitute for personalised medical advice, diagnosis, or treatment. Please consult your doctor or a healthcare professional regarding your specific health needs.
We hope you found this article informative. Healthful For You welcomes contributions from healthcare professionals, patients, and community members. If you have a story, research, or a perspective that can enrich our dialogue, please get in touch with us at [email protected].